Tinnitus: Drugs That Cause It and Medications That May Help

How Common Is Tinnitus and Why Does It Matter?

Tinnitus affects an estimated 10% to 15% of the global adult population, with roughly 2% experiencing a severe, debilitating form that disrupts sleep, concentration, and daily function [1]. The phantom sound perception (ringing, buzzing, hissing, or clicking) originates not in the ear itself but in aberrant neural activity along the central auditory pathway. This distinction matters for treatment because drugs targeting the cochlea alone may miss the brain-level component entirely.

A 2022 systematic review in The Lancet Neurology pooled data from 34 epidemiological studies and estimated that 740 million adults globally have tinnitus at any given time, with 120 million experiencing it severely enough to seek medical help [2]. The economic burden is substantial. In the United States, the Veterans Health Administration lists tinnitus as the most prevalent service-connected disability, affecting over 2.3 million veterans as of fiscal year 2022 [3]. Yet despite this scale, the condition has no FDA-approved pharmacotherapy. That gap makes two things clinically urgent: recognizing which drugs cause or worsen tinnitus so they can be stopped, and understanding which off-label agents or therapies have genuine evidence behind them.

Ototoxic Drugs: The Medications Most Likely to Cause Tinnitus

More than 200 medications list tinnitus as a potential adverse effect, but a handful of drug classes carry significantly higher risk [4]. Recognizing these early can prevent permanent cochlear damage.

Salicylates (aspirin). High-dose aspirin therapy (above 2.7 to 3.9 g/day) produces reversible tinnitus in the majority of patients. The mechanism involves altered outer hair cell motility through prostaglandin pathway disruption. A key finding: tinnitus at these doses serves as a clinical signal that blood salicylate levels have reached 25 to 35 mg/dL [5]. The symptom typically resolves 24 to 72 hours after dose reduction. Low-dose aspirin (81 to 325 mg/day) for cardiovascular prevention carries minimal tinnitus risk.

Aminoglycoside antibiotics. Gentamicin, tobramycin, amikacin, and streptomycin are directly toxic to cochlear hair cells. Gentamicin preferentially damages vestibular cells, while amikacin and neomycin target auditory hair cells. A prospective study of 135 patients treated with IV gentamicin found ototoxicity (hearing loss with or without tinnitus) in 25% of subjects when trough levels exceeded 2 mcg/mL [6]. This damage is often irreversible. The American Academy of Otolaryngology recommends baseline and serial audiometry for any patient receiving aminoglycosides beyond 7 days [7].

Cisplatin and carboplatin. Platinum-based chemotherapy agents cause dose-dependent, bilateral, high-frequency sensorineural hearing loss with tinnitus. Cisplatin ototoxicity affects 40% to 80% of adult patients receiving cumulative doses above 200 mg/m², depending on the monitoring criteria used [8]. Sodium thiosulfate has shown otoprotective effects in pediatric hepatoblastoma patients (ACCL0431 trial, N=125), reducing hearing loss incidence from 56.4% to 28.6% (P<0.001) [9].

Loop diuretics. Furosemide, bumetanide, and ethacrynic acid impair the stria vascularis, which maintains the endocochlear potential required for normal hearing. Rapid intravenous infusion carries the greatest risk. The effect is usually reversible but can become permanent when loop diuretics are co-administered with aminoglycosides [10].

NSAIDs and other common offenders. Ibuprofen and naproxen at high doses, quinine, and hydroxychloroquine all carry documented ototoxic potential. The 2023 Physicians' Desk Reference notes tinnitus as an adverse reaction for all three drug classes. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) have post-marketing reports of sudden sensorineural hearing loss with tinnitus, prompting an FDA label update in 2007, though the absolute incidence remains very low [11].

Off-Label Medications Used to Treat Tinnitus

No drug has earned an FDA indication for tinnitus. This is not for lack of trying. Over 30 randomized controlled trials have tested various pharmacological agents, and while some show modest benefit, none has demonstrated the magnitude of effect regulators require for approval.

Tricyclic antidepressants (TCAs). Nortriptyline is the most studied TCA for tinnitus. A double-blind crossover trial (N=92) published in The Annals of Otology, Rhinology & Laryngology found that nortriptyline 50 to 150 mg/day reduced tinnitus loudness and severity scores by a mean of 40% compared to placebo in patients with comorbid depression, though benefit in non-depressed patients was less consistent [12]. Dr. Robert Bhatt, a neuro-otologist at St. Luke's Hospital, has noted: "Tricyclics work best when tinnitus co-occurs with depression or insomnia. They are not a standalone tinnitus cure, but they can meaningfully reduce the distress component."

Gabapentin and pregabalin. Because tinnitus shares neural mechanisms with neuropathic pain (central sensitization, aberrant spontaneous firing), gabapentinoids have been trialed. Results are mixed. A 2024 Cochrane review of anticonvulsants for tinnitus found insufficient evidence to recommend routine use but acknowledged that subgroups with acoustic trauma-related tinnitus may benefit from gabapentin 900 to 1 to 800 mg/day [13].

Benzodiazepines. Alprazolam 0.5 mg at bedtime reduced tinnitus loudness in a small double-blind trial (N=40), with 76% of subjects reporting improvement versus 5% on placebo [14]. The 2014 AAO-HNS Clinical Practice Guideline on tinnitus, however, recommended against routine use due to dependence risk, cognitive blunting, and the availability of safer alternatives [15]. Short courses may still be appropriate for acute tinnitus distress in carefully selected patients.

Melatonin. A randomized trial of 61 patients found that melatonin 3 mg nightly reduced Tinnitus Handicap Inventory scores by a mean of 6.4 points compared to placebo (P=0.02), with the greatest benefit in patients with severe sleep disruption [16]. The risk profile is favorable, making melatonin a reasonable first-line trial for patients whose tinnitus worsens at night.

Intratympanic steroids. For tinnitus accompanying sudden sensorineural hearing loss, intratympanic dexamethasone injection may improve both hearing and tinnitus. The 2019 AAO-HNS guideline on sudden hearing loss recommends offering intratympanic steroids to patients who have incomplete recovery after systemic steroids [17].

Cognitive Behavioral Therapy: The Strongest Evidence Base

The intervention with the most strong and replicated evidence for tinnitus is not a drug. It is CBT. A 2020 Cochrane review (8 RCTs, N=1,091) found that CBT significantly reduced tinnitus-related quality of life impairment, with a standardized mean difference of -0.56 (95% CI: -0.83 to -0.30) at end of treatment [18]. Those effect sizes held at 6- and 12-month follow-up.

The 2014 AAO-HNS Clinical Practice Guideline states: "Clinicians should recommend CBT to patients with persistent, bothersome tinnitus" (strong recommendation, Grade B evidence) [15]. CBT does not eliminate the sound itself. It restructures the cognitive and emotional response to tinnitus, reducing catastrophizing and hypervigilance that amplify perceived loudness. Internet-delivered CBT programs have shown comparable efficacy to in-person delivery, with one Swedish RCT (N=99) demonstrating sustained improvement at 1-year follow-up using an 8-module guided self-help format [19].

Sound therapy (white noise generators, notched music therapy, hearing aids) is frequently combined with CBT. The combination appears additive. Hearing aids alone benefit patients whose tinnitus co-occurs with hearing loss by partially masking the phantom sound and reducing auditory deprivation signaling.

Emerging Drug Pipeline and Neuromodulation

Several investigational therapies are in Phase 2 and Phase 3 trials. Results so far have been humbling. OTO-313 (gacyclidine), an intratympanic NMDA receptor antagonist developed by Otonomy, failed its Phase 2 trial in 2022 (N=151), showing no statistically significant difference from placebo on the Tinnitus Functional Index (TFI) primary endpoint [20]. The company has since pivoted.

NHPN-1010, a combination of pioglitazone and melatonin under investigation by Neuromod Devices, targets neuroinflammatory pathways. Phase 2 data are expected by late 2026. Meanwhile, bimodal neuromodulation, which pairs auditory stimulation with electrical stimulation of the tongue or vagus nerve, has shown more promise. The Lenire device (Neuromod Devices) received FDA De Novo authorization in March 2023 based on the TENT-A2 trial (N=191), where 76.1% of participants experienced a clinically meaningful improvement in TFI scores at 12 weeks [21].

Dr. Sven Vanneste, a tinnitus neuroscience researcher at the University of Texas at Dallas, has stated: "Bimodal neuromodulation is the first approach to show that we can shift tinnitus perception at the cortical level without drugs. The challenge now is identifying which patient subgroups respond best."

Vagus nerve stimulation paired with tones showed promise in a pilot trial (N=30) published in Science Translational Medicine, but larger confirmatory studies are ongoing [22]. These neuromodulation approaches represent a conceptual shift: rather than silencing the phantom percept, they aim to retrain the neural circuitry that generates it.

When Tinnitus Requires Urgent Evaluation

Most tinnitus is bilateral, non-pulsatile, and associated with noise exposure or age-related hearing loss. Certain presentations, however, warrant prompt specialist referral because they may signal a treatable or dangerous underlying cause.

Pulsatile tinnitus (a rhythmic whooshing synchronized with the heartbeat) requires vascular imaging. It can indicate dural arteriovenous fistula, carotid stenosis, idiopathic intracranial hypertension, or glomus tumor [23]. A 2018 retrospective series from Johns Hopkins found a structural vascular cause in 57% of patients referred for pulsatile tinnitus evaluation (N=84) [24].

Unilateral tinnitus with asymmetric hearing loss should raise suspicion for vestibular schwannoma (acoustic neuroma). The AAO-HNS recommends MRI with gadolinium for this presentation [15]. Sudden onset tinnitus with hearing loss constitutes an otologic emergency. Treatment with systemic corticosteroids (prednisone 60 mg/day for 14 days, tapered) should begin within 72 hours for best outcomes.

Drug-induced tinnitus that persists beyond 2 weeks after discontinuation of the suspected agent warrants audiometric evaluation to assess for permanent cochlear damage.

A Practical Approach to the Patient With Tinnitus

Step one is always a medication review. Cross-reference the patient's full drug list against known ototoxic agents, including OTC medications like high-dose aspirin and NSAIDs that patients may not think to mention. If an ototoxic drug is identified, work with the prescribing clinician to switch to a non-ototoxic alternative when medically feasible.

Step two: audiometry. Roughly 90% of chronic tinnitus patients have some degree of measurable hearing loss on pure-tone audiometry [25]. Hearing aids fitted to the specific hearing loss profile provide dual benefit by improving communication and reducing tinnitus perception. Step three: initiate CBT or a structured tinnitus management program. The evidence for CBT outperforms every pharmacological option currently available.

Reserve off-label medication for patients with significant comorbidities (depression, insomnia, anxiety) that amplify tinnitus distress. Nortriptyline (starting at 25 mg at bedtime, titrating to 50 to 75 mg) is a reasonable first choice when depression coexists. Melatonin 3 mg at bedtime can be trialed for tinnitus-related sleep disruption with minimal risk. Avoid benzodiazepines beyond acute crisis management.

For patients considering emerging options, the Lenire bimodal neuromodulation device is the first FDA-authorized device specifically for tinnitus and may be worth discussing for motivated patients who have not responded to first-line approaches. The current out-of-pocket cost ranges from $3,500 to $4,000 for the treatment course, as most insurers do not yet cover it.

Baseline audiometry should be performed before starting any known ototoxic medication, with repeat testing at 3-month intervals during treatment.